Ensign Peak Advisors
ABVX icon

Ensign Peak Advisors’s Abivax ABVX Stock Holding History

Ensign Peak Advisors’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$41.8M Sell
422,320
-82,151
-16% -$9.9M 0.07% 214
2026
Q2 		$67.2M Sell
504,471
-127,367
-20% -$14.4M 0.11% 165
2026
Q1 		$70.4M Buy
631,838
+113,491
+22% +$13.4M 0.13% 151
2025
Q4 		$69.9M Buy
518,347
+62,663
+14% +$6.84M 0.12% 150
2025
Q3 		$38.7M Hold
455,684
– – 0.06% 230
2025
Q2 		$3.49M Hold
455,684
– – 0.01% 725
2025
Q1 		$2.85M Buy
+455,684
New +$3.08M 0.01% 782

Other funds holding ABVX

Helikon Investments
Helikon Investments London, United Kingdom $3.52B AUM 36.83% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $96.6B AUM 22.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Patient Square Capital
Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return

Ensign Peak Advisors's ABVX Position: Q3 2026 in Review

Ensign Peak Advisors reduced its Abivax (ABVX) stake by 16% in Q3 2026, selling an estimated $9.9M and leaving 422,320 shares worth $41.8M. The position accounts for 0.07% of the portfolio, ranked #214.

Ensign Peak Advisors first reported a position in ABVX in Q1 2025 and has held it in 7 quarters since. The position peaked at $70.4M in Q1 2026. 153 funds tracked by Wall St. Rank hold ABVX as of Q3 2026.

  • Ensign Peak Advisors held 422,320 shares of Abivax worth $41.8M as of Q3 2026.
  • Ensign Peak Advisors sold 82,151 Abivax shares in Q3 2026, an estimated $9.9M.
  • Abivax made up 0.07% of Ensign Peak Advisors's portfolio in Q3 2026, its #214 holding.
  • Ensign Peak Advisors first reported a position in Abivax in Q1 2025 and has held it in 7 quarters since.
  • Ensign Peak Advisors's Abivax position peaked at $70.4M in Q1 2026.
  • 153 funds tracked by Wall St. Rank held Abivax as of Q3 2026.

Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.